Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

The benchmark DAX index in Germany on Wednesday dropped by 3 percent as market turmoil triggered by U.S. tariff ...

Fresenius Medical Care AG (ETR:FME) has announced that it will be increasing its dividend from last year's comparable payment on the 27th of May to €1.44. This makes the dividend yield about the same ...

Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...

Under the terms of the settlement, Pacira has agreed to provide Fresenius with a license to its patents required to ...

Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement ...

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no ...

Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 ---- Fresen ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Bernstein analyst Lisa Bedell Clive maintained a Hold rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) today and set a price ...